CORT

Bullish

Korlym improves results for diabetes patients taking GLP-1 drugs

New analysis from the CATALYST clinical trial indicates that Korlym (mifepristone) can help lower blood sugar and promote weight loss in diabetes pati...

Cushing's Disease News Yesterday 0

Bullish

Is It Too Late To Look At Corcept Therapeutics (CORT) After The Recent Share Price Surge

Corcept Therapeutics (CORT) has seen significant share price growth, rising 96.0% year to date. Despite this surge, Simply Wall St's valuation models ...

Simply Wall Street 1 week ago 0